Jim Geraghty discusses rare diseases and his book “Inside The Orphan Drug Revolution: The Promise of Patient-Centered Biotechnology.
James Geraghty has been a director of eight NASDAQ-listed biotech companies and chair of five. He’s worked on orphan drugs for over forty years—as a strategy consultant, a CEO, a leader of pioneering international operations at Genzyme, and a venture entrepreneur. A former trustee of Harvard Medical School’s renowned Joslin Diabetes Center, he’s spoken before both houses of Congress, at the World Economic Forum, and at many other high-profile conferences. A Georgetown graduate with a Masters in psychology from Penn and a law degree from Yale, he is a citizen of three countries. He lives in Boston.